

## PUBLICATIONS

Juried or refereed journal articles and exhibitions:

- 1) Xia T, O'Hara A, Araujo I, Barreto J, Carvalho E, Sapucaia JB, **Ramos JC**, Luz E, Pedroso C, Manrique M, Toomey NL, Brites C, Dittmer DP, Harrington WJ Jr. Epstein-Barr virus microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. *Cancer Res* 68:1436-1442, 2008. **I contributed fresh primary tumor cells and with the analysis and interpretation of data obtained from these.**
- 2) Harhaj NS, Janic B, **Ramos JC**, Harrington WJ Jr, Harhaj EW. Deregulated expression of CD40 ligand in HTLV-I infection: Distinct mechanisms of downregulation in HTLV-I-transformed cell lines and ATL patients. *Virology*. 2007 (May 25); 362(1): 99-108. **I contributed fresh primary ATLL cells and with the analysis and interpretation of data obtained from these.**
- 3) **Ramos JC**, Ruiz Jr. P, Ratner L, Reis IM, Brites C, Pedroso C, Byrne Jr. GE, Toomey NL, Andela V, Harhaj EW, Lossos I, and Harrington Jr WJ. IRF-4 and c-Rel expression in antiviral therapy resistant adult T-cell leukemia/lymphoma. *Blood*. 2007 (Apr 1); 109(7): 3060-3068. **I designed and performed most of the experiments, analyzed data, and wrote the manuscript.**
- 4) Kurokawa M, Ghosh SK, **Ramos JC**, Mian AM, Toomey NL, Cabral L, Whitby D, Barber GN, Dittmer DP, Harrington Jr WJ. Azidothymidine inhibits NF- $\kappa$ B and induces Epstein-Barr virus gene expression in Burkitt lymphoma. *Blood*. 2005 Mar 24. **I performed and helped design some of the cell line experiments in vitro and electromobility shift assays.**
- 5) R. Razavi, **J.C. Ramos**, G. Yehia, F. Schlotter and C.A. Molina. ICER II $\gamma$  is a Tumor Suppressor the Mediates the Antiproliferative Activity of cAMP. *Oncogene* (Dec. 1998) 17. 3015-3019. **I performed most of the key work, including in vitro proliferation assays, soft agar experiments, and in vivo tumor growth assays in the nude mice.**

- 6) Casey, M. Lopez, **J.C. Ramos**, S. Plummer, J.E. Arboleda, M. Shaughnessy, B. Karlan, and D.J. Slamon. DNA Sequence Analysis of Exons 2 through 11 and Immunohistochemical Staining are Required to Detect All Known p53 Alterations in Human Malignancies. *Oncogene* 13(9) 1971 81,1996 Nov 7. **I processed and performed immunohistochemistry for P53 in large tumor cohorts and helped with P53 gene sequencing experiments.**
  - 7) W.J. Levin, G. Casey, **J.C. Ramos**, J. Arboleda, P.T. Reissmann and D.J. Slamon. Tumor suppressor and Immediate Early Transcription Factor Genes in Non-Small Cell Lung Cancer. *CHEST*; 106:6: 372-376 supplement; 1994. **I processed and performed immunohistochemistry for P53 in a large tumor cohort of the Lung Cancer Study Group and helped with P53 gene sequencing experiments.**
14. Poster presentations and abstracts:
- 1) **J. C. Ramos**, P. Ruiz, L. Ratner, I. M. Reis, C. Brites, C. Pedroso, G. E. Byrne, Jr., N. L. Toomey, V. Andela, E.W Harhaj, I. S. Lossos, and W. J. Harrington Jr. IRF-4 and Interferon Resistance in Adult T-cell Leukemia/lymphoma. *Blood* (ASH Annual Meeting Abstracts), Nov 2006; 108: 2531.
  - 2) **J.C. Ramos**, S.K. Ghosh, N.L. Toomey, M. Kurokawa, A. Luna, A. Mian, D. Dittmer, and W.J. International Conference Lymphoma... the Next Questions. San Juan, Puerto Rico, April 2-3, 2004 "AZT-mediated Inhibition of NF- $\kappa$ B: A Novel Therapy for Epstein Barr Virus Associated Lymphomas".
  - 3) **J.C. Ramos**, S.K. Gosh, M. Kurokawa, A.M. Mian, N.L. Toomey, D. Dittmer, W.J. Harrington Jr. Antiviral Mediated Suppression of NF- $\kappa$ B and Induction of Lytic Cycle: a Novel Therapy for EBV-Associated Burkitt Lymphoma. *Blood* 102 (11) 308b; 2003. Abstract: 4955
  - 4) **J. C. Ramos**, N.L. Toomey, S.K. Ghosh, N.C. Shank, L. Cabral, G.N. Barber, W.J. Harrington, Jr. Regression of Viral Lymphoproliferative Disease Through Antiviral Mediated Activation of TRAIL and Suppression of NF- $\kappa$ B. Poster: 2003 National AIDS Malignancy Conference, Bethesda, Maryland, U.S.A. Abstract: *Blood* 100 (111). Abstract: 3079
  - 5) **J.C. Ramos**, S.K. Gosh, L.Toomey, L. Cabral, N.C. Shank, G.N. Barber. W. J. Harrington. Successful Treatment with AZT and IFN- $\alpha$  in Adult T-Cell Leukemia-Lymphoma Is characterized by in Vivo Induction of TRAIL and AP-1 activity. Poster: 2002 American Society of Hematology Annual Conference, Philadelphia, U.S.A. Abstract: *AIDS Research and Human Retroviruses* 19 S-27.

- 6) **J.C. Ramos**, R. Razavi, G. Yehia, F. Schlotter and C.A. Molina. Poster: ICER II $\gamma$  is a Tumor Suppressor that Mediates the Antiproliferative Activity of cAMP. Cell Cycle Conference, Keystone Colorado 1997
- 7) P.T. Reissmann, R. Takashi, B. Giovanella, **J.C. Ramos**, M. Press, and D.J. Slamon. RB Gene Inactivation in Human Breast Cancer Specimens and Nude Mice Xenographs. Abstract: *Journal of Cellular Biochemistry* 16s: 147; 1992.

15. Oral presentations (State/National/International):

- 1) "IRF-4 and IFN Resistance in Adult T Cell Leukemia". International Conference on HTLV-I and Related Viruses. Hakone, Japan, 2007.
- 2) "NF- $\kappa$ B/REL Expression and Antiviral Resistance in Adult T-Cell Leukemia". III International Symposium of Oncovirology, Salvador-Bahia, Brazil. Nov 2005.
- 3) "AZT-mediated Inhibition of NF- $\kappa$ B: A Novel Therapy for Epstein Barr Virus Associated Lymphomas". Joint Cancer Conference of the Florida Universities, Orlando, FL. Feb 2004.
- 4) "Successful Treatment with AZT and IFN- $\alpha$  in Adult T-Cell Leukemia-Lymphoma is characterized by in Vivo Induction of TRAIL and AP-1 activity". 11<sup>th</sup> International Conference on Human Retrovirology, San Francisco, USA. June 2003